This interdisciplinary project brings together clinicians and basic scientists to investigate the novel tumor suppressor role of RUNX1 in breast cancer. The proposal will assess the prevalence of breat cancer tumors with aberrant RUNX1 function, not only RUNX1 mutations. Exploring the role of the RUNX1-WNT axis in breast cancer docetaxel resistance and the therapeutic potential of WNT/β-catenin modulating agents could lead to novel approaches for the management of breast cancer.

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.